Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
View Patent ↗The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
1. A method of treating asthma, osteoarthritis, dermatitis, inflammatory bowel disease, ulcerative colitis, or Crohn's disease, comprising administering to a patient in need thereof an effective amount of a pharmaceutical aqueous suspension comprising a plurality of moderate release biocompatible, therapeutic nanoparticles having a glass transition temperature between about 39° C. and about 41° C., wherein the nanoparticles comprise about 3 to about 40 weight percent of budesonide, and poly(lactic)acid-poly(ethylene)glycol, wherein the therapeutic nanoparticles have a diameter of about 80 nm to about 130 nm.
2. The method of claim 1 , wherein the poly(ethylene)glycol portion of the copolymer has a number average molecular weight of about 4 kDa to about 6 kDa.
3. The method of claim 1 , wherein the poly(lactic)acid portion of the copolymer has a number average molecular weight of about 15 kDa to about 20 kDa.
4. The method of claim 1 , wherein the poly(lactic)acid portion of the copolymer has a number average molecular weight of about 16 kDa, and the poly(ethylene)glycol portion of the copolymer has a number average molecular weight of about 5 kDa.
5. The method of claim 1 , comprising about 50 to about 90% by weight of the poly(lactic)acid-poly(ethylene)glycol copolymer.
6. The method of claim 1 , wherein the patient is suffering from inflammatory bowel disease.
7. The method of claim 1 , wherein the nanoparticles comprise about 4 to about 25 weight percent of the budesonide.
8. The method of claim 1 , wherein the nanoparticles comprise about 5 to about 30 weight percent of the budesonide.
9. A method of treating inflammatory bowel disease, comprising administering to a patient in need thereof an effective amount of a pharmaceutical suspension comprising a plurality of biocompatible, therapeutic nanoparticles having a glass transition temperature between about 39° C. and about 41° C. and a diameter of about 80 nm to about 130 nm, wherein the nanoparticles comprise: about 3 to about 40 weight percent of budesonide and poly(lactic)acid-poly(ethylene)glycol copolymer, wherein the poly(ethylene)glycol portion of the copolymer has a number average molecular weight of about 4 kDa to about 6 kDa, and the poly(lactic)acid portion of the copolymer has a number average molecular weight of about 15 kDa to about 20 kDa.